Payment plans

How does it work?

  • Reserve your order today and pay over time in regular, automatic payments.
  • You’ll receive your tickets and items once the final payment is complete.
  • No credit checks or third-party accounts - just simple, secure, automatic payments using your saved card.

Jumar Masterclass: Data Rooms, Capital Raising & Investor Readiness in Biotech

Share

Jumar Bioincubator
Melbourne VIC, Australia

Add to calendar

Thu, 26 Nov, 2:30pm - 5pm AEDT

Description

A practical session on building a data room that VCs, funders and pharma buyers can review with confidence


Great science opens the door, but investors and acquirers need more than promising data before they commit. They need to verify it, and the data room is where that happens. It turns your pitch into a clear, well-organised record investors can trust, and shows the operational discipline that gives them confidence in you.

Biotech data rooms are built around core elements: company overview, product or technology, evidence base, IP, regulatory strategy, market and competitor analysis, financials and team. The same structure applies whether you're a drug or device company, and whether you're raising from a VC, a strategic investor or heading into a buyout. What changes with stage is complexity, not structure. A seed-stage company might not have run a study yet, but the folder for it still exists, with the plan for that work inside. Your data room grows with your commercial plan, rather than being built from scratch each time.

Andrew Maxwell, MD of Chatsworth Associates, has reviewed hundreds of data rooms over his career. He'll walk us step by step through a typical data room outline, before our panel, who sit on the other side of the table, explore how it's read


What you'll learn

  • Aligning your data room with your pitch, so every claim is backed by a source document

  • Tools for organising, storing, sharing and protecting your data, and managing access at different deal stages

  • Responsible use of AI with confidential data

  • What reviewers look for in each area (science, regulatory, manufacturing, IP, commercial, team)

  • Being upfront about known risks, and why that builds credibility

  • What belongs in your investor memo

  • Common pitfalls that slow down rounds and deals

Who should attend

  • Start-ups and founders preparing for, or currently in, a capital raise, or thinking ahead to partnering or acquisition conversations

  • Researchers generating data for a potentially commercialisable product, particularly those from a scientific or technical background who want to understand the investor and buyer lens

  • Advisors, coaches and board members who support biotech ventures through funding and deal processes


You'll leave with

  • A practical data room framework you can apply immediately

  • A clearer picture of how different reviewers approach diligence

  • Strengthening confidence to walk into your next investor or partner conversation well prepared

Meet the Speakers

  • Andrew Maxwell, Founder and Managing Director of Chatsworth Associates

    Andrew Maxwell, Founder and Managing Director of Chatsworth Associates

    Andrew Maxwell is the Founder and Managing Director of Chatsworth Associates, a boutique advisory firm supporting emerging and high-growth companies in the bio-medical, medical device, mobile health and Health IT sectors. Over his career, Andrew has worked with innovators and entrepreneurs to plan and execute more than $350 million in equity and debt raisings, corporate transactions and international expansion programs. Andrew brings deep sector operational experience as the former Managing Director and CEO of Global Kinetics Corporation (GKC), where he led the commercialisation of neuroscience research in Parkinson’s disease. Under his leadership, GKC secured $22 million in equity funding, achieved FDA clearance and CE mark approvals, and implemented its technology in Europe, Asia and the USA. He is an active investor, is the chair of the Bond University’s School of Health Sciences & Medicine Advisory Board, Advisory Council member of the Turner Institute and serves as a Non-Executive Director and Chair guiding high-growth, technology-enabled organisations.

  • Katherine Jackman, Senior Investment Manager at Brandon Capital

    Katherine Jackman, Senior Investment Manager at Brandon Capital

    Katherine Jackman PhD MBA is the Senior Investment Manager at Brandon Capital and interim CEO of Axelia Oncology. Kath joined Brandon Capital in 2016. Prior to joining, Katherine worked in academia in the field of experimental stroke. She spent 5 years at Weill Cornell Medicine-New York Presbyterian Hospital as a NHMRC CJ Martin and American Australian Association Sir Keith Murdoch fellow where she focused on the impact of progranulin deficiency (a known cause of certain subtypes of dementia), on cerebral vascular integrity and susceptibility to stroke. Upon her return to Australia Katherine joined the Florey Institute of Neuroscience and Mental Health and began establishing herself as an independent researcher. During her time in academia, she published multiple research articles in top tier journals including J Neurosci & Stroke and secured competitive research funding from both the NHMRC and Brain Foundation of Australia. Katherine is a Director of NRG Therapeutics and Phrenix Therapeutics and a board observer of AstronauTx. Katherine has a Bachelor of Science (First-class Honours) from The University of Melbourne, a PhD in Pharmacology from The University of Melbourne and an MBA (Deans’ Honours list) from the Melbourne Business School. Katherine received Dean’s commendations in macroeconomics, business law, operations and entrepreneurship. Katherine is a graduate of the Australian Institute of Company Directors.

  • Michael Jorgensen, Senior Director, Global Business Development & Licensing, CSL

    Michael Jorgensen, Senior Director, Global Business Development & Licensing, CSL

    Dr Mike Jorgensen is Senior Director and Business Development Lead for Hematology at CSL. He has extensive experience evaluating and negotiating biotechnology partnering opportunities, from early-stage technologies through to clinical and commercial assets. Before joining CSL, Mike worked in business development and licensing roles at the University of Melbourne and King’s College London, having previously co-founded a Japanese-funded biotechnology company. He holds a PhD in Organic Chemistry and completed postdoctoral research at Yale University and Imperial College London.

  • Simon Preston, Chief of Staff at Atisama Therapeutics

    Simon Preston, Chief of Staff at Atisama Therapeutics

    Simon Preston is Chief of Staff at Atisama Therapeutics, a clinical-stage Melbourne biotech advancing RB042, an inhaled splice-switching oligonucleotide for COPD, following a AU$29M Series A and a AU$15M MRFF Frontiers award. He supports the CEO and Board on strategy, investor engagement and fundraising readiness, including building and maintaining the company’s data room, and runs its corporate operations across contracts, IP and finance. Simon has worked on both sides of the table: compiling data rooms and investor materials as Director of Clinical Research at ASX-listed BCAL Diagnostics, preparing university spinouts for investment as Venture Manager at SYNthesis Research, and assessing early-stage deals as an Investment Analyst at SYNthesis BioVentures. He holds a PhD from the University of Melbourne / WEHI and is an MBA candidate at Melbourne Business School.

Agenda

  • 2:30 pm

    Registrations

  • 3:00 pm

    Presentation by Andrew Maxwell from Chatsworth Associates

    A practical guide to building an investor-ready data room

  • 3:30 pm

    Panel Discussion

  • 4:30 pm

    Networking

  • 5:00 pm

    End

Important Note

  • The masterclass will be followed by an optional tour of Jumar Bioincubator. Let us know in the registration form if you're interested in participating.

  • You may be photographed or videoed while attending this event for marketing purposes: please approach the organiser if you have questions, concerns, or do not wish this to happen.

  • For security purposes, we kindly ask that all attendees bring a valid government-issued photo ID for registration upon arrival.

About Jumar Bioincubator

Jumar Bioincubator serves as a ‘first home’ for 30+ biotech ventures in Australia, providing affordable lab and office space alongside practical support to advance early scientific discoveries. Residents gain access to world-class facilities, a dedicated support team, and curated entrepreneurial training and events.

Established by CSL, WEHI and the University of Melbourne, and backed by Innovation Victoria with Cicada Innovations as operator, Jumar’s mission is to connect early-stage and scaling biotech ventures with the support needed to translate discoveries into real-world therapies and build a community of scientists equipped to lead successful biomedical ventures.

Powered by

Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity

Get tickets

Get tickets

Get tickets

Get tickets
Jumar Bioincubator
Melbourne VIC, Australia
Host icon
Hosted by Jumar Bio